Canadian Meds |
Policy | Legal
Terms | Meds Index
Diabetes mellitus - is always a pancreas malfunctions. In a healthy body insulin regulates blood sugar and promotes its absorption by cells. If the blood sugar level is lowered, then, under the action of glycogen its reserves are released from the liver. There comes a flagrant violation of the metabolism of fats, carbohydrates and proteins.
Propensity to diabetes is inherited, but the occurrence of the disease depends on many other factors.
Diabetes promote overweight, overeating, prolonged stress, some drugs (steroids, used to treat rheumatism, various allergies, asthma, diuretics, etc.), viral infections, autoimmune disorders. Young persons diabetes is most often caused by a virus.
What is Janumet and its indications for use?
Janumet is a combination of two hypoglycemic agents, metformin and sitagliptin, with complementary mechanism of action.
The medicine is shown as an adjunct to diet and exercise regime to improve glycemic control in patients with type II diabetes, who didnít get an adequate control with the help of metformin monotherapy or sitagliptin, or after a failure of combined treatment with these two drugs.
Janumet drug is also effective in combination with agonists of PPAR-? (thiazolidinediones) as an adjunct to diet and exercise regime to improve glycemic control in patients with type II diabetes.
Also, the drug is indicated to be taken with insulin to improve healthy profile and minimize side effects.
The dosing regimen of Janumet and contraindications
Janumet drug dosing regimen should be individualized and based on the current therapy, efficacy and tolerability, without exceeding the maximum recommended daily dose of 100 mg sitagliptin.
Usually, the drug is prescribed to be taken twice a day with meals, with gradual increase in dose, in order to minimize possible side effects from the gastrointestinal tract (GIT).
Initial dose of Janumet depends on the current hypoglycemic therapy.
Donít forget that only your physician, who is aware of your health condition, can set up the right Janumet initial dose and its further increase. Trusting your doctor in this case, you will achieve efficacy of therapy and avoid complications and side effects of curing. So, take this into account!
Itís not a secret, that Janumet has contraindications, like most of drugs. Consult a doctor about them in order to know them for sure. These contraindications include:
- hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of the formulation;
- acute conditions that may affect renal function: dehydration, severe infection, shock;
- acute or chronic disease which may cause tissue hypoxia, such as cardiac or respiratory failure, recent myocardial infarction, shock;
- moderate or severe renal impairment (creatinine clearance 60 ml / min);
- abnormal liver function;
- acute alcohol intoxication, alcoholism;
- type I diabetes;
- acute or chronic metabolic acidosis, including diabetic ketoacidosis (with or without coma);
- radiological investigations (intravascular iodinated contrast agents).
FDA approved the drug Janumet XR for the treatment of diabetes mellitus type 2
This year, the USA Food and Drug Administration has approved Janumet XR / metformin hydrochloride and sitagliptin tablets for the treatment of diabetes type 2.
The preparation includes sitagliptin, the active ingredient of the drug Janumet and metformin of prolonged action. Patients who need to monitor blood sugar levels, should take one tablet of Janumet XR a day.
The drug should be used in addition to diet and exercises to improve blood glucose levels in adult patients with diabetes mellitus type 2, which well tolerate the treatment with sitagliptin and metformin prolonged action. Janumet is not intended for use in patients with diabetes type 1 or with diabetic ketoacidosis.
We should notice, that Janumet drug research has not been conducted in patients with pancreatitis. Thus, there is no data, whether patients with pancreatitis are at increased risk of developing this disorder during treatment with Janumet XR.
FDA approval is based on results of clinical studies of bioequivalence, which showed that the drug Janumet is equivalent joint intake of appropriate doses of two drugs: sitagliptin and metformin hydrochloride. Prolonged action metformin has shown the same efficiency as quick-release metformin.
© 2003-2017 Rx Meds Canada . All Rights Reserved